Neuronetics Inc News Today

Neuronetics, Inc. (NASDAQ:STIM – Get Free Report) Director Robert Cascella acquired 50,000 shares of the firm’s stock in a transaction on Thursday, June 6th. The shares were bought at an average cost of $2.05 per share, with a total value of $102,500.00. Following the completion of the transaction, the director now directly owns 244,098 shares […]

Neuronetics, Inc. (NASDAQ:STIM – Get Free Report) Director Robert Cascella bought 50,000 shares of Neuronetics stock in a transaction on Thursday, June 6th. The stock was acquired at an average price of $2.05 per share, with a total value of $102,500.00. Following the completion of the purchase, the director now directly owns 244,098 shares of […]

Neuronetics, Inc. (NASDAQ:STIM – Get Free Report) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 18,000 shares, a decline of 69.1% from the April 30th total of 58,300 shares. Based on an average daily trading volume, of 176,600 shares, the days-to-cover ratio […]

MALVERN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who

Humana, a health insurance provider, has become the first commercial payer to cover TMS Therapy for adolescent depression.

Fielder Capital Group LLC bought a new stake in Neuronetics, Inc. (NASDAQ:STIM – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 22,797 shares of the company’s stock, valued at approximately $66,000. Fielder Capital Group LLC owned approximately 0.08% of Neuronetics at […]

Fielder Capital Group LLC bought a new stake in shares of Neuronetics, Inc. (NASDAQ:STIM – Free Report) in the fourth quarter, Holdings Channel reports. The institutional investor bought 22,797 shares of the company’s stock, valued at approximately $66,000. Other large investors also recently bought and sold shares of the company. FNY Investment Advisers LLC purchased […]

Neuromodulation Device Market by Product Type (Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators, Transcranial Magnetic Stimulator), by Type (Invasive, Non - invasive), by Application, by End User, by

/PRNewswire/ - Greenbrook TMS Inc. (OTCQB: GBNHF) ("Greenbrook" or the "Company") today announced its fiscal year ended December 31, 2023 ("Fiscal 2023")...

Neuronetics, Inc. (NASDAQ:STIM – Get Free Report) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 94,600 shares, a growth of 77.8% from the March 15th total of 53,200 shares. Based on an average daily volume of 199,100 shares, the days-to-cover ratio is […]